New combo therapy aims to boost immune attack on mesothelioma
NCT ID NCT05765084
First seen Jun 09, 2026 · Last updated Jun 16, 2026 · Updated 2 times
Summary
This study tests adding an immunotherapy drug (atezolizumab) and a personalized vaccine (WT1/DC) to standard chemotherapy for people with a type of mesothelioma. The goal is to see if this combination is safe and helps the immune system fight the cancer better. About 15 adults with epithelioid malignant pleural mesothelioma will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL MESOTHELIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AZ Maria Middelares
RECRUITINGGhent, 9000, Belgium
Contact
-
Antwerp University Hospital
RECRUITINGEdegem, Antwerp, 2650, Belgium
Contact Email: •••••@•••••
-
VITAZ
RECRUITINGSint-Niklaas, 9100, Belgium
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.